QualityDipStocks / Health Care · Pharmaceuticals
Viking Therapeutics VKTX
Outside our quality screen, so we don’t track its dips. It’s 36% below its 52-week high.
Outside our quality screen. No fair value estimate for now: there isn’t enough data.
- Fair value est.
- n/a
- Market Value
- forming
- Off 52-wk high
- −36%
- Risk vs market
- Above marketbeta 1.17
0 bullish · 4 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for VKTX: Capital spending isn't tagged in SEC XBRL data. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much VKTX moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings more than the market, and its own price swings are 5.4× the S&P 500’s.
- Beta vs S&P 500
- 1.17
- Volatility
- 68% vs 13% SPY
- Correlation SPY
- 0.22
- Correlation QQQ
- 0.19
Valuation details
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 0 of 5
Nothing in our data makes a clear bull case right now.
Top bearish points 4 of 5
ProfitabilityLost $627M over the last 12 months (net income, SEC filings).
ProfitabilityReturn on equity fell 32 points in two fiscal years, to -56% in FY2025.
Cash returnsShare count up 5.1% in a year: existing holders are being diluted.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%; no sales-growth data.
All fundamentals
ROE -96%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anot reported in its SEC filings
- FCF yield
- n/anot reported in its SEC filings
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- n/anot reported in its SEC filings
- Price / book
- 5.78×
- Market cap
- $3.4Blisted
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $0
- Sales growth, 12 months
- n/ano year-ago 12-month revenue
- Sales growth, 3 yrs
- n/anot reported in its SEC filings
- Diluted EPS, 12 months
- −$5.42
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$627M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- n/anot reported in its SEC filings
- Net margin
- n/anot reported in its SEC filings
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- −96%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $960M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- n/anot reported in its SEC filings
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +5.1%diluted shares vs a year ago
- Stock-based comp
- $48M
Trailing 12 months to Sep 30, 2026; balance sheet at Sep 30, 2026. From Viking Therapeutics’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
- Gross margin0%
- Operating margin0%
- Return on equity−96%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $26.83
- 52-wk lowlowest close, 1 year$24.21−9.8%
- PriceMon Nov 2 close$26.83you are here
- 52-wk highhighest close, 1 year$42.13+57.0%
Momentum & 52-week range
RSI 46 · 5 days +10.8%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
VKTX is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Viking Therapeutics in the last 48 hours. Headlines as published, each linked. Their words, not ours.
UBSAnalyst rating changeAnalyst
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.The Motley Fool ·
Checked Nov 3, 1:01 PM ET. Matched by name against a maintained list plus the company’s own executives. Information only, not advice.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.